March 13th 2023
The final analysis of the phase 2/3 CCTG IND.227/KEYNOTE-483 trial identifies a statistically significant survival benefit with pembrolizumab and chemotherapy vs chemotherapy alone in the first-line setting for patients with unresectable advanced or metastatic malignant pleural mesothelioma.
Community Practice Connections™: Pathology Oncology Collaborative: Biomarker Testing in an Emerging Era of HER2 Across Breast, GI, and Lung Cancers
Equalizing Inequities™ in Multiple Myeloma Care: Shining a Light on Current Barriers and Opportunities for Improved Outcomes
Clinical Vignettes: 40th Annual CFS®: Innovative Cancer Therapy for Tomorrow®
Trekking Through the Latest Updates for ROS1-Targeted Therapies
Community Practice Connections™: 6th Annual Precision Medicine Through Plasma™ – Using Liquid Biopsies in Contemporary Oncology Care
Mapping Out the Role of Emerging Biomarkers and Testing in NSCLC
Navigating the Latest Data on NTRK-Targeted Therapies
Community Practice Connections™: 17th Annual New York Lung Cancers Symposium
Medical Crossfire®: Antibody-Drug Conjugates Coming to Your Oncology Practice Tomorrow
Show Me Your Care Plan™: Monitoring and Managing Patients With EGFR Exon20 Insertion+ NSCLC
Burst CME™ - Part II – Advent of HER3 Targeted Approaches and Rationale in NSCLC Care
Burst CME™ - Part I – Overview of Pathophysiology, Diagnosis, and Management of HER3 Expressing Cancers
Burst CME™ - Part III – Advent of HER3 Targeted Approaches and Rationale in Breast Cancer Care
Advancing Precision Care Through Biomarker-Driven Therapy: CEACAM5 as a Therapeutic Target in NSCLC
Virtual Testing Board: Digging Deeper on Your Testing Reports to Elevate Patient Outcomes in Advanced Non–Small Cell Lung Cancer
Medical Crossfire: How Should We Leverage Multidisciplinary Lung Cancer Care Teams in Managing Earlier Forms of NSCLC... When the Goal Is Cure?
Virtual Show Me the Data™: How HER2, HER3, and TROP2 Targeted Strategies Will Impact Evolving Paradigms in NSCLC
Catching Them Early: A Real-World Case Discussion on the Application of Testing Methodologies to Identify Key Markers Across NSCLC
Expert Illustrations & Commentaries™: Exploring the Clinical Rationale for Antagonizing Inflammatory IL-1-beta Signaling in NSCLC
Onco-Nurse Academy™: Exploring an Advent of Targeted Therapies Across Advanced NSCLC Care and Strategies for Managing Adverse Events Associated With Treatment
Patient, Provider, and Caregiver Connection™: Shedding a Light on the Patient Journey with KRAS Mutated Lung Cancer
Clinical Vignettes®: Multidisciplinary Discussions on the Application of Novel EGFR Exon 20 Targeted Regimens for NSCLC Management
Expert Illustrations & Commentaries™: Exploring the Role of Novel Antibody-Drug Conjugates in Advanced NSCLC
Advances In™ NSCLC: Exploring CEACAM5 As A New Therapeutic Target
Community Practice Connections™: Top 10 Oncogenic Markers in NSCLC for 2022: Evolution of Tumor Testing Technologies, Novel Treatments, and Trials!
Community Practice Connections™: Analyzing the Evolving Role of Liquid Biopsies Across Cancer Care
Advances In™: The Role of NRG1 Fusions Across Tumor Types
Medical Crossfire®: Leveraging EGFR Mutation Profiles to Personalize Therapeutic Decisions in Resected and Metastatic NSCLC Settings
Expert Illustrations & Commentaries™: The Role of B7-H3 Across Tumor Types and How It Could Impact Your Practice in the Future
Top 10 Oncogenic Markers in NSCLC for 2022: Evolution of Tumor Testing Technologies, Novel Treatments, and Trials!
Adding Nivolumab to Chemotherapy Improves Outcomes in Resectable NSCLCJune 7th 2021
The addition of neoadjuvant nivolumab plus platinum-doublet chemotherapy significantly improved pathological complete response rates and showed a greater depth of pathological response compared with chemotherapy alone in patients with resectable non–small cell lung cancer.
Adjuvant Gefitnib Fails to Induce Superior DFS, OS Versus Chemo in EGFR-mutant NSCLCJune 6th 2021
Although adjuvant treatment with gefitinib delayed early relapse in patients with completely resected EGFR-mutant non–small cell lung cancer, the agent did not significantly improve disease-free survival or overall survival compared with cisplatin/vinorelbine.
Pralsetinib Shows Durable Anti-Tumor Activity in Study Update for RET+ Solid TumorsJune 6th 2021
Pralsetinib was well tolerated, while demonstrating robust and durable anti-tumor activity when treating heavily pretreated patients with multiple RET fusion–positive advanced solid tumors.
Neoadjuvant Nivolumab Plus Chemo Improves Pathological Complete Response in Resectable NSCLCApril 10th 2021
The CheckMate-816 trial is the first positive phase 3 trial demonstrating a significant improvement in pathologic response with neoadjuvant immunotherapy plus chemotherapy in resectable non-small cell lung cancer.
Diagnostic AI Tool for Identifying Early-Stage Lung Cancer Earns FDA 150(k) ClearanceMarch 24th 2021
The Virtual Nodule Clinic artificial intelligence–powered clinical decision support tool was cleared by the FDA for detection of early-stage lung cancer in lung nodules detected by a CT scan.
Study Results Appear to Support Larotrectinib Use in NTRK+ Lung CancerFebruary 20th 2021
Patients with advanced lung cancer whose tumors harbor an NTRK gene fusion with or without central nervous system metastases were found to have high response rates, durable responses, and extended survival benefit with larotrectinib.
Further Patient Education by Clinicians Is Necessary to Facilitate Better Decision MakingJanuary 28th 2021
“With recent advances in early detection of lung cancer, biomarker testing, and personalized treatment planning, effective patient-provider communication is more important than ever for short- and long-term survivorship,” said Kelly Clark, MA.
FDA Grants Breakthrough Therapy Designation to Tiragolumab Combo for PD-L1-High NSCLCJanuary 5th 2021
The combination of tiragolumab and atezolizumab (Tecentriq) was granted breakthrough therapy designation based on promising efficacy and safety data observed in the phase 2 CITYSCAPE trial.
FDA Grants Priority Review to sNDA for Lorlatinib in Previously Untreated ALK+ NSCLCJanuary 4th 2021
Under the FDA’s Real-Time Oncology Review Pilot Program and Project ORBIS, the FDA is reviewing a supplemental new drug application for lorlatinib (Lorbrena) as a first-line treatment for patients with ALK-positive metastatic non–small cell lung cancer.
Latin American Patients with Lung Cancer and Native American Ancestry See Increased EGFR MutationsDecember 22nd 2020
This study found that among patients with lung cancer from Latin America, Native American ancestry was associated with increased mutations in the EGFR gene, independent of smoking status.
FDA Approves Osimertinib as Adjuvant Therapy Following Resection of NSCLC with EGFR MutationsDecember 18th 2020
Full approval has been granted by the FDA to osimertinib (Tagrisso) for use as adjuvant therapy following tumor resection among patients with non–small cell lung cancer whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations.
Albert Rizzo, MD, on the Annual State of Lung Cancer ReportDecember 12th 2020
The American Lung Association’s annual “State of Lung Cancer” (SOLC) report tracked the toll of lung cancer at national and state levels, identifying both promising improvements for the overall population and significant health disparities for racial and ethnic minorities.
FDA Grants Breakthrough Therapy Designation to Sotorasib for NSCLC with KRAS G12C MutationDecember 8th 2020
The FDA granted breakthrough therapy designation to sotorasib for the treatment of patients with locally advanced or metastatic non-small cell lung cancer with KRAS G12C mutation, as determined by an FDA-approved test, following at least 1 prior systemic therapy.
Janssen Submits BLA for Amivantamab to Treat Metastatic NSCLC with EGFR Exon 20 Insertion MutationsDecember 3rd 2020
Janssen submitted a biologics license application to the FDA seeking approval of amivantamab for the treatment of patients with metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations whose disease has progressed on or after platinum-based chemotherapy.
State-Level Lung Cancer Screening Rates Do Not Align with Lung Cancer BurdenNovember 26th 2020
This study found that state-level lung cancer screening rates were not aligned with disease burden, with the exception of Kentucky, which has supported comprehensive efforts to implement lung cancer screening.
Study Finds Racial Disparities in ES-NSCLC Persist Despite Gains in TreatmentNovember 25th 2020
Though researchers found that Black patients with early-stage non-small cell lung cancer are now more likely to receive the most effective treatment compared to a decade ago, the disparity for this patient population persists.
Phase 3 CROWN Trial Shows Promise for Lorlatinib in Previously Untreated ALK-Positive NSCLCNovember 23rd 2020
An interim analysis of the trial revealed that among patients with previously untreated advanced ALK-positive non-small cell lung cancer, those who received lorlatinib (Lorbrena) had significantly longer PFS, a higher overall and intracranial response, and better quality of life.
Osimertinib Extends Disease-Free Survival in Resected EGFR-Mutated NSCLC in Phase 3 ADAURA TrialNovember 21st 2020
These study results suggest that osimertinib as adjuvant therapy is an effective treatment strategy for patients with stage IB to IIIA EGFR-positive non-small cell lung cancer following complete tumor resection.
Steven M. Dubinett, MD, on Early Lung Cancer Development and Testing MethodsNovember 20th 2020
The SU2C–LUNGevity Foundation–American Lung Association Lung Cancer Interception Dream Team have developed laboratory models to understand the inflammatory process in the lung’s bronchial cells, and how that relates to early lung cancer development.
FDA Approves Additional Dosing Option of Durvalumab for Stage III NSCLC, Advanced Bladder CancerNovember 20th 2020
The FDA approved a 1500 mg fixed dose of durvalumab (Imfinzi) administered every 4 weeks for the treatment of unresectable stage III non-small cell lung cancer after chemoradiation therapy and previously treated advanced bladder cancer.
Phase 3 RATIONALE 303 Meets Primary End Point of OS in NSCLCNovember 18th 2020
The clinical trial is designed to evaluate the efficacy and safety of tislelizumab compared to docetaxel in the second- or third-line setting in patients with locally advanced or metastatic non-small cell lung cancer who have progressed on a prior platinum-based chemotherapy.
Patients with Early-Stage NSCLC See Higher TMB Versus Those with Advanced Stage NSCLCNovember 15th 2020
Researchers suggested that the tumors of patients with stage I and II early-stage non-small cell lung cancer demonstrate the highest tumor mutational burden and most often display the mutational signature associated with tobacco smoking.